Treatment with anti-γ-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice

Journal of Bone and Mineral Research

Volumn 22, Issue 12, 2007, Pages 1933-1942

  Ishizuka, Yasuyuki ^a,b   Moriwaki, Sawako ^b   Kawahara Hanaoka, Miyuki ^c   Uemura, Yasunori ^d   Serizawa, Isao ^d   Miyauchi, Mutsumi ^e   Shibata, Shunichi ^f,g   Kanaya, Toshimichi ^h   Takata, Takashi ^e   Taniguchi, Naoyuki ^g   Niida, Shumpei ^b  

^a Applied Cell Biotechnologies Inc   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c Ishida Dental and Orthodontic Clinic   (Japan)

^d KIRIN BREWERY CO LTD   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^h Kitayama Labes Co Ltd   (Japan)

Author keywords

glutamyl transpeptidase; Antibody therapy; Arthritis; Osteoclast; Osteolysis

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG; BONE RESORPTION FACTOR; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BAGG ALBINO MOUSE; BONE EROSION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; JOINT DESTRUCTION; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PLASMA CELL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; STEM CELL; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; CYTOKINES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFLAMMATION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; RATS; RATS, WISTAR; STEM CELLS;

EID: 38749150369     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070726     Document Type: Article

References (34)

1. Goldring SR, Gravalles LM 2002 Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 2:226-231.
2. Feldmann M, Brenna FM, Marini RN 1996 Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440.
3. Theill LE, Boyle WJ, Penninger M 2002 RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795-823.
4. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D 2004 The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457-475.
5. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, Koshihara Y 1997 A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 240:279-286.
6. Takayanagi H 2005 Inflammatory bone destruction and osteoimmnnology. J Periodont Res 40:287-293.
7. Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T 2002 The molecular mechanism of osteoclaslogenesis in rheumatoid arthritis. Arthritis Res 4:281-289.
8. Ishizuka Y, Mochizuki R, Yanai K, Takatsuka M, Nonomura T, Niida S, Horiguchi H, Maeda N, Fukamizu A 1999 Induction of hydroxyapatite resorptive activity in bone marrow cell populations resistant to bafilomycin A1 by a factor with restricted expression to bone and brain, neurochondrin. Biochim Biophys Acta 1450:92-98.
9. Niida S, Kawahara M, Ishizuka Y, Ikeda Y, Kondo T, Hibi T, Suzuki Y, Ikeda K, Taniguchi N 2004 Gamma glutamyltranspeptidase stimulates receptor activator of nuclear factor-kappaB ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor. J Biol Chem 279:5752-5756.
10. Lieberman MW, Barrios R, Carter BZ, Habib GM, Lebovitz RM, Rajagopalan S, Sepulveda AR, Shi Z-Z, Wan D-F 1995 gamma-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Am J Pathol 147:1175-1185.
11. Hiramatsu K, Asaba Y, Takeshita S, Nimura Y, Tatsumi S, Katagiri N, Niida S, Nakajima T, Tanaka S, Ito M, Karsenty G, Ikeda K 2007 Overexpression of γ-glutamyltransferase in transgenic mice accelerates bone resorption and causes osteoporosis. Endocrinology 148:2708-2715.
12. Hanigan MH, Frierson HF Jr 1996 Immunohistochemical detection of gamma glutamyl transpeptidase in normal human tissue. J Histochem Cytochem 44:1101-1108.
13. Novogrodsky A, Tate SS, Meister A 1976 gamma-Glutamyl transpeptidase, a lymphoid cell-surface marker: Relationship to histogenesis, differentiation, and neoplasia. Proc Natl Acad Sci USA 73:2414-2418.
14. Grisk O, Kuster U, Ansorge S 1993 The activity of gamma glutamyl transpeptidase (gamma-GT) in populations of mononuclear cells from human peripheral blood. Biol Chem Hoppe Seyler 374:287-290.
15. Carlisle ML, King MR, Karp DR 2003 Gamma-glulamyl transpeptidase activity alters the T cell response to oxidative stress and Fas-induced apoptosis. Int Immunol 15:17-27.
16. Lawrence BP, Will Y, Reed DJ, Kerkvliet NI 2000 Gamma- glutamyltranspeptidase knockout mice as a model for understanding the consequences of diminished glutathione on T cell-dependent immune responses. Eur J Immunol 30:1902-1910.
17. Karp DR, Carlisle ML, Mobley AB, Nichols TC, Oppenheimer-Marks N, Brezinschek RI, Holers VM 1999 Gamma-glutamyl transpeptidase is up-regulated on memory T lymphocytes. Int Immunol 11:1791-1800.
18. Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H 1986 Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum 29:400-410.
19. Ikeda Y, Fujii J, Taniguchi N, Meister A 1995 Expression of an active glycosylated human gamma-glutamyl transpeptidase mutant that lacks a membrane anchor domain. Proc Natl Acad Sci USA 92:126-130.
20. Miyauchi M, Sato S, Kitagawa S, Hiraoka M, Kudo Y, Ogawa I, Zhao M, Takata T 2001 Cytokine expression in rat molar gingival periodontal tissues after topical application of lipopolysaccharide. Histochem Cell Biol 116:57-62.
21. Suzuki Y, Nishikaku F, Nakatuka M, Koga Y 1998 Osleoclast-like cells in murine collagen induced arthritis. J Rheumatol 25:1154-1160.
22. Suzuki Y, Tsutsumi Y, Nakagawa M, Suzuki H, Matsushita K, Beppu M, Aoki H, Ichikawa Y, Mizushima Y 2001 Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology 40:673-682.
23. Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, Sasamata M, Harada S, Akama H, Tazaki H, Chung U, Takato T, Nakamura K, Kawaguchi H 2006 Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J Bone Miner Res 21:219-227.
24. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT 1997 Interleukin-18 (interferon-gamma inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 185:1005-1012.
25. Mochizuki A, Takami M, Kawawa T, Suzumoto R, Sasaki T, Shiba A, Tsukasaki H, Zhao B, Yasuhara R, Suzawa T, Miyamoto Y, Yongwon C, Kamijo R 2006 Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activation of NF-kB ligand. J Immunol 177:4360-4368.
26. Shomer NH, Fox JG, Juedes AE, Ruddle NH 2003 Helicobacter-induced chronic activity lymphoid aggregates have characteristics of tertiary lymphoid tissue. Infect Immunol 71:3572-3577.
27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
28. Mapp PI, Grootveld MC, Blake DR 1995 Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 51:419-436.
29. Tak PP, Zvaifler NJ, Green DR, Firestein GS 2000 Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases. Immunol Today 21:78-82.
30. Feldmann M, Maini RN 2003 TNF define as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9:1245-1250.
31. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM 2001 Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104.
32. Rratcher JM, Korelitz BI 2006 Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 5:9-16.
33. Kamijo S, Nakajima A, Ikeda K, Aoki K, Ohya K, Akiba H, Yagita H, Okumura K 2006 Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun 347:124-132.
34. Straub RH, Harle P, Yamana S, Matsuda T, Takasugi K, Kishimoto T, Nishimoto N 2006 Anti-interleukin 6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study. Arthritis Rheum 54:1778-1785.